Your browser doesn't support javascript.
loading
Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies.
Leavitt, Victoria M; Dworkin, Jordan D; Galioto, Rachel; Ratzan, Alexander S.
Afiliação
  • Leavitt VM; Department of Neurology, Columbia University Irving Medical Center, 168th Street, P&S Box 16, New York 10032, NY, United States. Electronic address: VL2337@cumc.columbia.edu.
  • Dworkin JD; Department of Psychiatry, Columbia University and the New York State Psychiatric Institute, New York, NY, United States.
  • Galioto R; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, Ohio, United States.
  • Ratzan AS; Department of Neurology, Columbia University Irving Medical Center, 168th Street, P&S Box 16, New York 10032, NY, United States.
Mult Scler Relat Disord ; 85: 105508, 2024 May.
Article em En | MEDLINE | ID: mdl-38452646
ABSTRACT

BACKGROUND:

Current treatment guidelines recommend consideration of disease-modifying therapy (DMT) for all multiple sclerosis (MS) patients, but barriers to access have begun to be identified. In particular, prior studies have found that people with higher education have better access to DMTs, perhaps explained by the association of higher education with higher income. And while the majority of people with MS are women, being male is also associated with higher income. These factors argue for the need to better understand whether there are differences in DMT uptake based on sex and education. Finally, in addition to well-documented benefits of DMTs for slowing disease progression, there is growing evidence to suggest benefits of DMTs for cognitive functioning.

OBJECTIVE:

Determine whether rates of DMT treatment differ based on education and sex. Secondarily, we investigate whether neurocognitive test performance differs in treated versus not treated groups.

METHODS:

In cross-sectional data, mixed effects linear regression evaluated differences in education and sex of those treated versus not treated with DMTs. Models included the following predictors age, disease duration, MS subtype, sex/education, disability, atrophy, and T2 lesion volume. Propensity score weights were extracted to obtain unbiased estimates of the relationship between DMT status and each outcome of interest. The same models evaluated performance differences between groups on an iPad-based processing speed test (PST) and manual dexterity test (MDT).

RESULTS:

Controlling for covariates, individuals with less education (OR=1.09, 95 % CI=[1.03, 1.14], p = 0.003) and women (OR=0.80, 95 % CI=[0.72, 0.90], p < 0.001) were less likely to be currently treated with DMTs. Small effect size association was shown for DMT treatment with better performance on PST (beta=0.09, CI=[0.06, 0.13], p < 0.001) and MDT (beta=0.05, CI=[0.01,0.08], p = 0.011).

CONCLUSIONS:

Women and people with lower education had a lower likelihood of being currently treated with DMTs. After controlling for all relevant variables, an independent (small) association of DMT treatment to better performance on tests of processing speed and fine motor dexterity was found. Reasons for disparities remain to be investigated in future work, and may include employment status, health insurance coverage, or sex differences in risk tolerance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escolaridade / Esclerose Múltipla Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escolaridade / Esclerose Múltipla Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article